Recently, Professor Jiang Hulin's team from the School of Pharmacy has published a series of latest research results on the treatment of pulmonary fibrosis in the top journals of the discipline, Advanced Functional Materials and Journal of Controlled Release.
Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease with insidious onset, and the median survival after clinical diagnosis is only 2-4 years. Factors such as microbial infection, radiation, or dust pollution can induce sustained damage to type II alveolar epithelial cells, promote fibroblast activation, excessively secrete extracellular matrix (ECM), and gradually replace the parenchymal tissue of normal alveoli, ultimately leading to impaired respiratory function and even endangering life. Inhalation administration is an effective way to treat lung diseases, but the mucous barrier in the trachea and ECM barrier in the stroma hinder the efficiency of inhalation administration and interfere with its therapeutic effect. In response to this issue, Professor Jiang Hulin's team utilized TCEP and L-arginine to construct a double-layer barrier to penetrate liposomes and improve drug delivery efficiency. The research findings were published in Advanced Functional Materials under the title Dual barrier penalizing inhaled nanoparticles for enhanced intellectual pulmonary fibrosis therapy. Yang Mingyuan, a master's graduate from the School of Pharmacy, Han Mengmeng, a doctoral student, and Tang Ling, a master's student, were the co first authors of this article, while Professor Jiang Hulin and postdoctoral Wang Yi, as well as Professor Jee Heon Jeong from Sungkyunkwan University in South Korea, were the co corresponding authors.
Full text link: https://doi.org/10.1002/adfm.202315128
As pulmonary fibrosis worsens, abnormal airway epithelial cells migrate to the alveoli, proliferate malignant and differentiate into airway cells that produce mucin, forming honeycomb like cysts and exacerbating the progression of IPF. Based on this, Professor Jiang Hulin's team has developed a dual drug loaded nanoparticle that effectively inhibits fluidization of airway epithelial cells and excessive activation of fibroblasts, prevents the formation of honeycomb like cysts and interstitial remodeling, and ultimately effectively treats IPF. The research findings were published in the Journal of Controlled Release under the title Inhaled nanoparticles for treating idiopathic pulmonary fibrosis by invading honeycomb cycle and alveoli interstitium remodelling. Dr. Han Mengmeng from the School of Pharmacy, Dr. Tang Ling from the Master's degree program, Dr. Huang Bin from the Second Affiliated Hospital of Zhejiang University School of Medicine are the co first authors of this article, and Professor Jiang Hulin is the only corresponding author.
Full text link: https://doi.org/10.1016/j.jconrel.2024.01.032
The above work has been supported by key international (regional) cooperative research projects and general projects of the National Natural Science Foundation of China, key research and development plans of the Ministry of Science and Technology, and research projects of the National Key Laboratory of Multi target Natural Drugs at China Pharmaceutical University.
